What is a common complication associated with chronic use of metoclopramide?

What is a common complication associated with chronic use of metoclopramide?

• A. Hyperglycemia
• B. Tardive dyskinesia
• C. Constipation
• D. Hyperlipidemia

Answer: (B)

Chronic use of metoclopramide is associated with tardive dyskinesia, which is a movement disorder characterized by involuntary and often repetitive movements, particularly of the face and mouth. This condition arises due to prolonged dopamine receptor antagonism, which is a key mechanism of action for metoclopramide as it blocks dopamine receptors to enhance gastrointestinal motility and decrease nausea. Patients who are on metoclopramide for extended periods, especially those treated for conditions such as gastroparesis or chronic nausea, are at an increased risk for developing tardive dyskinesia. The risk escalates with the duration of treatment and cumulative dosage, making it particularly important for healthcare providers to monitor patients closely for any emergence of involuntary movements during long-term therapy. Understanding this relationship highlights the need for careful patient selection and ongoing evaluation of the necessity for metoclopramide therapy, balancing the benefits against potential adverse effects like tardive dyskinesia. Other options listed—hyperglycemia, constipation, and hyperlipidemia—are not commonly associated with chronic metoclopramide use, thereby reinforcing the significance of tardive dyskinesia as a serious complication for long-term users of this medication.

Chronic use of metoclopramide is associated with tardive dyskinesia, which is a movement disorder characterized by involuntary and often repetitive movements, particularly of the face and mouth. This condition arises due to prolonged dopamine receptor antagonism, which is a key mechanism of action for metoclopramide as it blocks dopamine receptors to enhance gastrointestinal motility and decrease nausea.

Patients who are on metoclopramide for extended periods, especially those treated for conditions such as gastroparesis or chronic nausea, are at an increased risk for developing tardive dyskinesia. The risk escalates with the duration of treatment and cumulative dosage, making it particularly important for healthcare providers to monitor patients closely for any emergence of involuntary movements during long-term therapy.

Understanding this relationship highlights the need for careful patient selection and ongoing evaluation of the necessity for metoclopramide therapy, balancing the benefits against potential adverse effects like tardive dyskinesia. Other options listed—hyperglycemia, constipation, and hyperlipidemia—are not commonly associated with chronic metoclopramide use, thereby reinforcing the significance of tardive dyskinesia as a serious complication for long-term users of this medication.